A phase II trial of concomitant interferon-α-2b and granulocyte- macrophage colony-stimulating factor in patients with advanced renal cell carcinoma

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This study was undertaken to test the hypothesis that the combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-α- 2b (INF-α) would have a favorable clinical impact on patients with advanced renal cell carcinoma. Fifteen patients were treated with INF-α, 5 million U/m2 three times a week and GM-CSF 5 μg/kg, subcutaneously, daily. Patients received two consecutive 4-week cycles and then restaged. There were no complete responses, two of 15 partial responses (13%), and 13 of 15 had no response (87%). Biological effects (eosinophilia and leukocytosis) were characteristically observed. The therapy was well tolerated, and most side effects were attributable to INF-α. The study failed to show that the addition of GM-CSF to INF-α would increase the response rate in patients with metastatic renal cell carcinoma by enhancement of macrophage tumoricidal activity.

Original languageEnglish (US)
Pages (from-to)58-61
Number of pages4
JournalJournal of Immunotherapy
Volume17
Issue number1
StatePublished - 1995

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Renal Cell Carcinoma
Interferons
Leukocytosis
Eosinophilia
Macrophages
Therapeutics

Keywords

  • Granulocyte-macrophage colony- stimulating factor
  • Immunotherapy
  • Interferon-α-2b
  • Macrophage
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

@article{de7baceea680454eb5550da69a2727f6,
title = "A phase II trial of concomitant interferon-α-2b and granulocyte- macrophage colony-stimulating factor in patients with advanced renal cell carcinoma",
abstract = "This study was undertaken to test the hypothesis that the combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-α- 2b (INF-α) would have a favorable clinical impact on patients with advanced renal cell carcinoma. Fifteen patients were treated with INF-α, 5 million U/m2 three times a week and GM-CSF 5 μg/kg, subcutaneously, daily. Patients received two consecutive 4-week cycles and then restaged. There were no complete responses, two of 15 partial responses (13{\%}), and 13 of 15 had no response (87{\%}). Biological effects (eosinophilia and leukocytosis) were characteristically observed. The therapy was well tolerated, and most side effects were attributable to INF-α. The study failed to show that the addition of GM-CSF to INF-α would increase the response rate in patients with metastatic renal cell carcinoma by enhancement of macrophage tumoricidal activity.",
keywords = "Granulocyte-macrophage colony- stimulating factor, Immunotherapy, Interferon-α-2b, Macrophage, Renal cell carcinoma",
author = "O'Donnell, {Robert T} and G. Dea and Meyers, {Frederick J}",
year = "1995",
language = "English (US)",
volume = "17",
pages = "58--61",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A phase II trial of concomitant interferon-α-2b and granulocyte- macrophage colony-stimulating factor in patients with advanced renal cell carcinoma

AU - O'Donnell, Robert T

AU - Dea, G.

AU - Meyers, Frederick J

PY - 1995

Y1 - 1995

N2 - This study was undertaken to test the hypothesis that the combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-α- 2b (INF-α) would have a favorable clinical impact on patients with advanced renal cell carcinoma. Fifteen patients were treated with INF-α, 5 million U/m2 three times a week and GM-CSF 5 μg/kg, subcutaneously, daily. Patients received two consecutive 4-week cycles and then restaged. There were no complete responses, two of 15 partial responses (13%), and 13 of 15 had no response (87%). Biological effects (eosinophilia and leukocytosis) were characteristically observed. The therapy was well tolerated, and most side effects were attributable to INF-α. The study failed to show that the addition of GM-CSF to INF-α would increase the response rate in patients with metastatic renal cell carcinoma by enhancement of macrophage tumoricidal activity.

AB - This study was undertaken to test the hypothesis that the combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-α- 2b (INF-α) would have a favorable clinical impact on patients with advanced renal cell carcinoma. Fifteen patients were treated with INF-α, 5 million U/m2 three times a week and GM-CSF 5 μg/kg, subcutaneously, daily. Patients received two consecutive 4-week cycles and then restaged. There were no complete responses, two of 15 partial responses (13%), and 13 of 15 had no response (87%). Biological effects (eosinophilia and leukocytosis) were characteristically observed. The therapy was well tolerated, and most side effects were attributable to INF-α. The study failed to show that the addition of GM-CSF to INF-α would increase the response rate in patients with metastatic renal cell carcinoma by enhancement of macrophage tumoricidal activity.

KW - Granulocyte-macrophage colony- stimulating factor

KW - Immunotherapy

KW - Interferon-α-2b

KW - Macrophage

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0028815476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028815476&partnerID=8YFLogxK

M3 - Article

C2 - 7728306

AN - SCOPUS:0028815476

VL - 17

SP - 58

EP - 61

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -